RxDoctor Payments Data

John Oliga, MD

Internal Medicine · Decatur, GANPI 1013021781

Payments from drug & device makers

$567in general payments, 2019–2025

Across 15 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$107
  • AstraZeneca$105
  • Viiv Healthcare Company$93
  • Otsuka America Pharmaceutical, Inc.$74
  • Bayer$56
  • Lilly USA, LLC$32
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$567 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$14,699
Medicare patients
25
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$92,928
JardianceEmpagliflozin42$57,260
EliquisApixaban50$43,066
TrulicityDulaglutide17$33,565
XareltoRivaroxaban20$29,261
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,177
FarxigaDapagliflozin Propanediol29$22,271
JanuviaSitagliptin Phosphate19$17,006
MyrbetriqMirabegron22$13,448
Tresiba Flextouch U-100Insulin Degludec21$11,415
SymbicortBudesonide/Formoterol Fumarate15$5,174
Albuterol Sulfate HfaAlbuterol Sulfate130$5,072
Advair HfaFluticasone Propion/Salmeterol12$4,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$3,514
Novolog FlexpenInsulin Aspart17$3,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$107$43,06650 claims
Lilly USA, LLCTrulicity$32$33,56517 claims
AstraZenecaFarxiga, Symbicort$105$27,44544 claims
MerckJanuvia$19$17,00619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →